NEWS

BioGenCell has completed the 6 Months follow-up

BioGenCell has completed the 6 Months follow-up in its first in human, phase I/II clinical trial in CLI patients (clinicaltrials.gov Identifier: NCT02805023). Results of this cohort of patients show that the treatment is safe and has therapeutic effects in both

Read More »

BioGenCell has welcomed aboard Prof. Aaron Ciechanover

BioGenCell has welcomed aboard Prof. Aaron Ciechanover, the Nobel Prize Laureate (2004, chemistry). Prof. Ciechanover has joined BioGenCell’s Scientific Advisory Board and is renowned for his groundbreaking discoveries on the ubiquitin system and its major roles in homeostasis and in

Read More »

BioGenCell’s clinical study PI, Dr. Mark Niven

BioGenCell’s clinical study PI, Dr. Mark Niven, a worldwide leader in the field of diabetes and the Director of the Endocrine and Diabetes Unit, incorporating the Bildirici Center for Diabetes Care and Research at Laniado Hospital, Israel, gave a scientific

Read More »

full chapter for a peer-reviewed textbook

BioGenCell and its colleagues wrote a full chapter for a peer-reviewed textbook which describes among things the method and rationale behind its clinical trial. The Scientific publication of the chapter ‘Cell Therapy for Vascular Diseases in Israel’ appears in the

Read More »